Literature DB >> 25605038

Quantification and significance of diffuse myocardial fibrosis and diastolic dysfunction in childhood hypertrophic cardiomyopathy.

Tarique Hussain1, Andreea Dragulescu, Lee Benson, Shi-Joon Yoo, Howard Meng, Jonathan Windram, Derek Wong, Andreas Greiser, Mark Friedberg, Luc Mertens, Michael Seed, Andrew Redington, Lars Grosse-Wortmann.   

Abstract

The purpose of this study was to evaluate the presence of diffuse myocardial fibrosis in children and adolescents with hypertrophic cardiomyopathy (HCM) and to assess associations with echocardiographic and clinical parameters of disease. While a common end point in adults with HCM, it is unclear whether diffuse myocardial fibrosis occurs early in the disease. Cardiac magnetic resonance (CMR) estimation of myocardial post-contrast longitudinal relaxation time (T1) is an increasingly used method to estimate diffuse fibrosis. T1 measurements were taken using standard multi-breath-hold spoiled gradient echo phase-sensitive inversion-recovery CMR before and 15 min after the injection of gadolinium. The tissue-blood partition coefficient was calculated as a function of the ratio of T1 change of myocardium compared with blood. An echocardiogram and blood brain natriuretic peptide (BNP) levels were obtained on the day of the CMR. Twelve controls (mean age 12.8 years; 7 male) and 28 patients with HCM (mean age 12.8 years; 21 male) participated. The partition coefficient for both septal (0.27 ± 0.17 vs. 0.13 ± 0.09; p = 0.03) and lateral walls (0.22 ± 0.09 vs. 0.07 ± 0.10; p < 0.001) was increased in patients compared with controls. Eight patients had overt areas of late gadolinium enhancement (LGE). These patients did not show increased partition coefficient compared with those without LGE (0.27 ± 0.15 vs. 0.27 ± 0.19 and 0.22 ± 0.09 vs. 0.22 ± 0.09; p = 0.95 and 0.98, respectively). However, patients who were symptomatic (dyspnea, arrhythmia and/or chest pain) had higher lateral wall partition coefficient than asymptomatic HCM patients (0.27 ± 0.08 vs. 0.17 ± 0.08; p = 0.006). Similarly, patients with raised BNP (>100 pg/ml) had raised lateral wall coefficients (0.27 ± 0.07 vs. 0.20 ± 0.07; p = 0.03), as did those with traditional risk factors for sudden death (0.27 ± 0.06 vs. 0.18 ± 0.08; p = 0.007). Diffuse fibrosis, measured by the partition coefficient technique, is demonstrable in children and adolescents with HCM. Markers of fibrosis show an association with symptoms and raised serum BNP. Further study of the prognostic implication of this technique in young patients with HCM is warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25605038     DOI: 10.1007/s00246-015-1107-7

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  33 in total

Review 1.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista
Journal:  J Am Soc Echocardiogr       Date:  2009-02       Impact factor: 5.251

2.  Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study.

Authors:  R A Nishimura; C P Appleton; M M Redfield; D M Ilstrup; D R Holmes; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

3.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease.

Authors:  A M Varnava; P M Elliott; S Sharma; W J McKenna; M J Davies
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

4.  Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography.

Authors:  Tomoko S Kato; Akiko Noda; Hideo Izawa; Akira Yamada; Koji Obata; Kohzo Nagata; Mitsunori Iwase; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

5.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

6.  Interpretation of left ventricular diastolic dysfunction in children with cardiomyopathy by echocardiography: problems and limitations.

Authors:  Andreea Dragulescu; Luc Mertens; Mark K Friedberg
Journal:  Circ Cardiovasc Imaging       Date:  2013-01-23       Impact factor: 7.792

7.  B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy.

Authors:  J P Kaski; M T Tomé-Esteban; S Mead-Regan; A Pantazis; J Marek; J E Deanfield; W J McKenna; P M Elliott
Journal:  Heart       Date:  2007-12-10       Impact factor: 5.994

8.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.

Authors:  Leah Iles; Heinz Pfluger; Arintaya Phrommintikul; Joshi Cherayath; Pelin Aksit; Sandeep N Gupta; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

9.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy.

Authors:  Valentina O Puntmann; Tobias Voigt; Zhong Chen; Manuel Mayr; Rashed Karim; Kawal Rhode; Ana Pastor; Gerald Carr-White; Reza Razavi; Tobias Schaeffter; Eike Nagel
Journal:  JACC Cardiovasc Imaging       Date:  2013-03-14

10.  Modified look-locker inversion recovery T1 mapping indices: assessment of accuracy and reproducibility between magnetic resonance scanners.

Authors:  Fabio S Raman; Nadine Kawel-Boehm; Neville Gai; Melanie Freed; Jing Han; Chia-Ying Liu; Joao A C Lima; David A Bluemke; Songtao Liu
Journal:  J Cardiovasc Magn Reson       Date:  2013-07-26       Impact factor: 5.364

View more
  13 in total

Review 1.  Utility of late gadolinium enhancement in pediatric cardiac MRI.

Authors:  Maryam Etesami; Robert C Gilkeson; Prabhakar Rajiah
Journal:  Pediatr Radiol       Date:  2015-12-30

2.  3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.

Authors:  Liang Yin; Hai-Yan Xu; Sui-Sheng Zheng; Ying Zhu; Jiang-Xi Xiao; Wei Zhou; Si-Si Yu; Liang-Geng Gong
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-13       Impact factor: 2.357

3.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Authors:  Anna Axelsson Raja; Hoshang Farhad; Anne Marie Valente; John-Paul Couce; John Lynn Jefferies; Henning Bundgaard; Kenneth Zahka; Harry Lever; Anne M Murphy; Euan Ashley; Sharlene M Day; Mark V Sherrid; Ling Shi; David A Bluemke; Charles E Canter; Steven D Colan; Carolyn Y Ho
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

4.  Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Chia-Ying Liu; Susan R Heckbert; Shenghan Lai; Bharath Ambale-Venkatesh; Mohammad R Ostovaneh; Robyn L McClelland; João A C Lima; David A Bluemke
Journal:  J Am Coll Cardiol       Date:  2017-12-26       Impact factor: 24.094

Review 5.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the Use of Cardiac Magnetic Resonance in Pediatric Congenital and Acquired Heart Disease: Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  Circ Cardiovasc Imaging       Date:  2022-06-21       Impact factor: 8.589

Review 6.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the use of cardiovascular magnetic resonance in pediatric congenital and acquired heart disease : Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-21       Impact factor: 6.903

7.  T1 mapping in children and young adults with hypertrophic cardiomyopathy.

Authors:  Keyur Parekh; Michael Markl; Jie Deng; Roger A de Freitas; Cynthia K Rigsby
Journal:  Int J Cardiovasc Imaging       Date:  2016-09-22       Impact factor: 2.357

8.  Myocardial extracellular volume fraction quantification in an animal model of the doxorubicin-induced myocardial fibrosis: a synthetic hematocrit method using 3T cardiac magnetic resonance.

Authors:  Zhen Zhou; Rui Wang; Hui Wang; Yi Liu; Dongxu Lu; Zhonghua Sun; Guang Yang; Lei Xu
Journal:  Quant Imaging Med Surg       Date:  2021-02

Review 9.  Sirtuins in the Cardiovascular System: Potential Targets in Pediatric Cardiology.

Authors:  Alessandro Ianni; Xuejun Yuan; Eva Bober; Thomas Braun
Journal:  Pediatr Cardiol       Date:  2018-03-02       Impact factor: 1.655

10.  The myocardial protective effect of monosodium phosphate cardioplegia in cardiopulmonary bypass in infants with an atrial septal defect.

Authors:  Fang Yang; Jie Wang; Bo Zhai
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.